The treatment of the hemolytic-uremic syndrome with inhibitors of platelet function.
In four patients with clinical and laboratory manifestations of the hemolytic-uremic syndrome, the administration of aspirin and dipyridamole was associated with a dramatic and rapid increase in the platelet count. In three of the four patients there was also improvement in neurologic or renal function. No subject experienced bleeding or other untoward effects. We conclude that a trial of aspirin and dipyridamole therapy is warranted early in the course of the hemolytic-uremic syndrome.
D000328:Adult; D001241:Aspirin / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects; D002452:Cell Count / Q000187:drug effects; D004176:Dipyridamole / Q000627:therapeutic use*; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000473:pathology; D008297:Male; D011225:Pre-Eclampsia / Q000150:complications; D011247:Pregnancy
D004176:Dipyridamole; D001241:Aspirin